Inhaled Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Safety
研究概览
简要总结
Idiopathic pulmonary fibrosis(IPF) is chronic progressive fibrosing lung disease of unknown cause. There is no effective therapy yet for this disease and the mean survival in most reports is about 3 years after the diagnosis. Because of the stiff fibrosis of the lung, pulmonary hypertension is the late complication of IPF and its development heralds a very poor outcome of the patients. For the primary pulmonary hypertension, recently the effective drugs have been available. However, there is no study about the efficacy of these drugs in the patients with pulmonary hypertension secondary to pulmnary fibrosis, and the aim of this trial is to study the safty and efficacy of "Iloprost," one of the safe and effective drugs in primary pulmonary hypertension.
详细描述
- Prospective open labeled observational study
- Subjects: About 15 patients with secondary pulmonary hypertension due to IPF or pulmonary fibrosis associated with collagen vascular diseases.
- Method: 3 month trial of inhaled iloprost. Check the safty and measure the pulmonary arterial pressure by right heart catheterization, exercise capacity by 6 minute walking test, echocardiography, and quality of life questionnaires before and after the trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of idiopathic pulmonary fibrosis or fibrotic NSIP according to American Thoracic Society and European Respiratory Society guidelines by biopsy and diagnosis of pulmonary fibrosis associated with connective tissue disease.
- •Mean pulmonary artery pressure over 30mmHg.
- •NYHA functional class II to IV
排除标准
- •Suffering lung diseases other than pulmonary fibrosis (COPD, Pulmonary Thromboendarterectomy ).
- •Administration of prostanoids, bosentan, beta- blocker or phosphodiesterase5 inhibitor.
- •Dosage adjustment of calcium channel blockers within 6 weeks.
- •Resting pulmonary capillary wedge pressure over 15mmHg.
- •Bleeding tendency.
- •Bilirubin level above 3mg/dl or creatinine clearance level below 30ml/min.
- •Unstable angina pectoris, myocardial infarction or severe arrhythmia within 6 months.
- •Cerebrovascular accident within 6 months.
- •Present lung infection.
结局指标
主要结局
Safety
Pulmonary arterial pressure
Exercise capacity (6 minute walking test)
次要结局
- 6 minute walking test: Min. oxygen saturation.
- NYHA class,
- Quality of life (St. George Respiratory questionnaires)
- Pulmonary vascular resistance, cardiac output.
- Increment of pulmonary arterial pressure after the exercise
- 6) Pulmonary function test